Riskpilot← Back to searchSign inGet full accessPEPTIDE PATENTS AS
ASActiveOrg 922687374Sykehusvegen 23, 9019 TromsøLeasing of intellectual property and similar products, except copyrighted works · NACE 7740Est. 20190 employees
Revenue 2024
NOK 900K
-17% vs 2023
EBITDA margin
12.9%
+64% vs 2023
Equity ratio
57.8%
Financial strength
Net profit 2024
NOK 43K
+361% vs 2023
| Revenue | NOK 900K | -17% |
| EBITDA | NOK 116K | +64% |
| Net profit | NOK 43K | +361% |
| Total assets | NOK 1,2M | +10% |
| Equity | NOK 697K | +7% |
| Employees | 0 | — |
Legal name
PEPTIDE PATENTS AS
Org number
922687374
Legal form
Aksjeselskap
NACE code
7740 · Leasing of intellectual property and similar products, except copyrighted works
Founded
29. april 2019
Share capital
NOK 1 000 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap tegner selskapets firma.
Company purpose
Forvalte imaterielle rettigheter, samt det som naturlig står i forbindelse med dette. Selskapet har ikke adgang til å selge eierskap til immaterielle rettigheter eller pantsette slike, men bare utlisensiere slike.
Address
Sykehusvegen 23, 9019 Tromsø
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 246 | 827 | 787 | 1 082 | 900 |
| Staff expenses | −0 | −66 | −0 | −0 | −0 |
| EBITDA | 10 | 2 | −42 | 71 | 116 |
| Depreciation & amort. | −120 | −80 | −80 | −80 | −80 |
| EBIT | −110 | −78 | −122 | −9 | 36 |
| Net financials | −10 | −2 | −2 | −8 | 7 |
| Profit before tax | −120 | −80 | −124 | −17 | 43 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −120 | −80 | −124 | −17 | 43 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 475 | 1 167 | 1 098 | 1 097 | 1 206 |
| Equity | 874 | 794 | 671 | 654 | 697 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 600 | 372 | 427 | 443 | 509 |
| Total debt | 600 | 372 | 427 | 443 | 509 |
EBITDA margin
12.9%
This company
15.8%
Market median
-18% vs market
20202024
Equity ratio
57.8%
This company
38.2%
Market median
+51% vs market
20202024
Return on equity
6.2%
This company
18.4%
Market median
-66% vs market
20202024
Net profit margin
4.8%
This company
8.1%
Market median
-41% vs market
20202024
Asset turnover
0.75×
This company
1.12×
Market median
-33% vs market
20202024
Debt / equity
0.73×
This company
0.62×
Market median
+18% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
TE Contact Person | Contact Person | 2024 |
| Former (1) | ||
KV Contact Person | Contact Person | 2021 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2020 | |
| Board of Directors | 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 50% | 50% | 2024 | |
| Company | 50% | 50% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
As Holding
PEPTIDE PATENTS AS Board members of PEPTIDE PATENTS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kjetil Vangsnes | Contact Person | 0 companies |
| Torsteinn Erlingsson | Contact Person | 0 companies |
| Erik Rosen | Chairman | 0 companies |
| Christian Georg Lütken | Board of Directors | 0 companies |